Back to search results

Study of Nicotinamide Riboside for Combined Pulmonary Hypertension

This study is looking into nicotinamide riboside (NR), a dietary supplement, as a potential treatment for combined pre-/post-capillary pulmonary hypertension (CPH). CPH is a serious heart and lung condition with no approved treatments. Researchers identified NR as a promising option using advanced computer methods. You may be able to join if you are 18-85 years old and have been diagnosed with CPH. The study will measure changes in a specific biochemical marker and your 6-minute walk distance to see if NR has an effect. The study is currently recruiting 10 participants, but its overall status is unclear.

Study design
This is an interventional study where participants will be randomly assigned to receive either nicotinamide riboside or a placebo. There will be 10 participants in total.
What's involved
You would receive either nicotinamide riboside or a placebo daily for 6 weeks, followed by a 3-week break, and then the alternate treatment for another 6 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be measured at baseline, Week 6, Week 9, and Week 15.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07563322

Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension

Recruiting
NAAges 18–85InterventionalTreatment
Vanderbilt University Medical Center
~10 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Nicotinamide Riboside (NR)Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Biochemical: Change in NADH:Ubiquinone Oxidoreductase Subunit B7
Measured over Baseline, Week 6, Week 9, Week 15
+1 more outcome measured

Conditions

Pulmonary Hypertension

Explore related trials

Pulmonary Hypertension

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Evan L Brittain, MD · PRINCIPAL_INVESTIGATOR · VUMC

Who to contact

Thomas E Strayer, PhD
[email protected]
615-936-0156
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged \>/= 18 to 85 years of age
Diagnosis of Combined pre-/post-capillary PH (CPH) defined as mean pulmonary artery pressure \>20mmHg, pulmonary capillary wedge pressure \>15mmHg, and pulmonary vascular resistance ³3 Wood units
NYHA Class I - III
A qualifying Baseline RHC performed within 2 years of consent Clinical echocardiogram within the prior year with LVEF\>/= 45%
Stable PH-specific and/or HF medication regimen and ≤1 diuretic adjustment within the three months prior to enrollment.
Ambulatory - able to perform the walk test

Exclusion

Pulmonary hypertension due to congenital heart disease, connective tissue disease, or heritable pulmonary arterial hypertension
Prohibited from regular activity due to wheelchair bound status, bed-bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other conditions that limit activity
Pregnancy
Drug and toxin-associated PAH patients with active drug use
Prior or active diagnosis of cirrhosis
Active Malignancy
Patients with evidence of moderate to severe hepatic impairment, defined as Child-Pugh Class B or C, or with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 3 times the upper limit of normal (ULN), should be excluded
eGFR by MDRD \<30mL/mi
FEV1\< 60% predicted with more than mild abnormalities on lung imaging Current enrollment in or completion of any other investigational product study within 30 days of Screening.
Hospitalization for any indication within 30 days of Day 1.
History of severe allergic or anaphylactic reaction or hypersensitivity to NR
No known mutation in NDUFB7

What this trial measures

  • Biochemical: Change in NADH:Ubiquinone Oxidoreductase Subunit B7Baseline, Week 6, Week 9, Week 15
  • Exploratory physiological measure: Change in 6-minute walk distanceBaseline, Week 6, Week 9, Week 15

    The 6MWT measures the distance (in meters), a participant can walk at a comfortable speed on a flat, hard surface in 6 minutes. The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out daily physical activities.